Roar Biomedical

Executive Summary

Roar Biomedical is a specialized biotechnology company developing and commercializing novel fluorescence-based activity assays for drug discovery and clinical research, with a focus on lipid metabolism enzymes such as CETP and LCAT. These enzymes are critical targets in cardiovascular and metabolic diseases, and Roar's assays provide a sensitive, high-throughput platform for screening modulators. The company's products are already cited in hundreds of scientific publications and patents, indicating strong validation within the academic and pharmaceutical research communities. Headquartered in San Francisco and operating in the digital health and diagnostics categories, Roar serves a niche but essential market segment, enabling researchers to accurately measure enzyme activity in complex biological samples. Given its established product portfolio and scientific credibility, Roar Biomedical is well-positioned to capitalize on the growing demand for specialized assay tools in drug discovery. The company operates at the intersection of biotechnology and diagnostics, offering solutions that accelerate the development of therapies for cardiovascular diseases—a leading cause of death globally. While Roar remains private with limited disclosed funding, its technology platform has the potential for broader application beyond lipid metabolism, including other enzyme classes. The key challenge will be scaling commercialization and expanding into new therapeutic areas, but the company's deep expertise and existing customer base provide a solid foundation for growth.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation multiplex activity assay platform60% success
• Q3 2026Strategic partnership with a major pharmaceutical company for CETP inhibitor screening50% success
• Q2 2026Publication of key validation study in a high-impact journal75% success